The primary objective of the JOINT Monitoring study is to assess the impact of telemonitoring on the effects, measured in PROMS, and the costs considering a societal perspective, in Rheumatoid Arthritis patients.
ID
Source
Brief title
Condition
- Autoimmune disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameters are the effects measured in Patient Reported
Outcomes, making use of the EQ-5D questionnaires and the societal costs
associated with the implementation of telemonitoring amongst RA patients.
Secondary outcome
N/A
Background summary
The conventional healthcare provision is shifting more and more from hospitals
to the living room of RA patients in an attempt to improve the value of
healthcare delivered to patients. As a result of COVID-19, the uptake of
e-health and telecare has increased. E-health and telemonitoring are considered
as promising methods to observe patients remotely, thereby easing the burden
for patients and shifting to a patient-centered healthcare system. Furthermore,
telemonitoring is expected to become part of the usual care delivered by
hospitals. In the JOINT Monitoring study we will introduce telemonitoring by
the remote controlling of essential laboratory results and performing
e-consultations.
Study objective
The primary objective of the JOINT Monitoring study is to assess the impact of
telemonitoring on the effects, measured in PROMS, and the costs considering a
societal perspective, in Rheumatoid Arthritis patients.
Study design
In the JOINT Monitoring study, we will conduct a cost-effectiveness analysis
considering a societal perspective. The research design following the
cost-effectiveness study, is a non-randomized control study that will be
performed at the outpatient department of the Maasstad Hospital, the Albert
Schweitzer Hospital and the Medisch Spectrum Twente. The follow-up period will
be 12 months.
Intervention
Applying the use of lancets at home for the (tele)monitoring of the essential
laboratory results and the e-consultation is the intervention. The intervention
is the shift from blood sampling and consultation at the hospital site to the
home of the patient.
Study burden and risks
We qualified the risk of this study based on the guideline by the NFU (Dutch
Federation of University Medical Centers) about quality insurance in human
research (*Kwaliteitsborging van mensgebonden onderzoek*). The NFU guideline
states that the extent of risk has to be estimated by considering the
additional risk of an intervention compared to standard treatment.
Maasstadweg 21
Rotterdam 3079DZ
NL
Maasstadweg 21
Rotterdam 3079DZ
NL
Listed location countries
Age
Inclusion criteria
- Diagnosis of rheumatoid arthritis as stated by the rheumatologist;
- Reported Patient Reported Outcomes Measures;
- Minimum age of 18 years;
- Able to provide informed consent;
- Literacy in Dutch.
Exclusion criteria
- Arthritis other than rheumatoid arthritis;
- Unable to take blood samples via lancets.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL77176.100.21 |